VirTus Respiratory Research has played a key role in the development of Apollo Therapeutics’ APL-10456, supporting the programme through more than five years of preclinical research. Through over 20 studies, VirTus helped evaluate vaccine candidates, establish proof...
Virtus Respiratory Research Ltd is pleased to share that our collaboration with AltesaBiosciences, Inc. has contributed to the successful close of a $75 million oversubscribedSeries B financing.The financing follows positive results from a Phase 2a human rhinovirus...
LONDON – VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa...
